title: Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
abstract: Identify predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP).
  
  
  
  Retrospective analysis.
  
  
  
  Patients with RMHNSCC treated with CP were identified and patient data was recorded. The Kaplan-Meier method was used to estimate outcomes, and Cox regression analysis was used to examine outcome predictors.
  
  
  
  Fifty-nine patients initiated CP between January 2007 and June 2014. Median age was 56 (range: 39-80) years. The most common primary sites were the oropharynx in 22 (37%) patients, oral cavity in 19 (32%), and larynx in 11 (19%). Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 in seven (12%), 1 in 32 (54%), and 2 in 16 (28%) patients. In 44 (75%) patients, CP was used as a first-line R/M regimen. Median number of cycles was five (range: 1-29). Dose modifications were necessary in 27 (46%) patients. The objective response rate was 47.5%, with 27 (45.8%) partial responses and one (2%) complete response. With a median follow-up of 13.4 months, median progression-free (PFS) and overall survival (OS) were 7.7 and 13.2 months, respectively. On multivariable analysis, an ECOG of 2 of 3 was associated with inferior OS (hazard ratio [HR]: 3.94; P = 0.01; 95% confidence interval [CI]: 1.1-14.04) and PFS (HR: 7.29; P < 0.01; 95% CI: 2.1-26.0) compared to an ECOG 0 of 1. First-line CP administration was associated with superior PFS compared to second line (HR: 2.6; P = 0.02; 95% CI:1.2-5.5).
  
  
  
  CP is well tolerated in this population of patients, with favorable tumor efficacy. First-line use and an ECOG 0 of 1 points appears to confer superior outcomes.
  
  
  
  4. Laryngoscope, 127:1583-1588, 2017.
authors.affiliation: Department of Medicine, University of Central Florida College of Medicine, Orlando, Florida, U.S.A.
authors.forename: Bruna
authors.initials: B
authors.lastname: Pellini Ferreira
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, U.S.A.
authors.forename: Mary
authors.initials: M
authors.lastname: Redman
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, U.S.A.
authors.forename: Kelsey K
authors.initials: KK
authors.lastname: Baker
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Renato
authors.initials: R
authors.lastname: Martins
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Keith D
authors.initials: KD
authors.lastname: Eaton
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Laura Quan Man
authors.initials: LQM
authors.lastname: Chow
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Christina S
authors.initials: CS
authors.lastname: Baik
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Bernardo
authors.initials: B
authors.lastname: Goulart
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Sylvia Mina
authors.initials: SM
authors.lastname: Lee
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Rafael
authors.initials: R
authors.lastname: Santana-Davila
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, U.S.A.
authors.forename: Cristina P
authors.initials: CP
authors.lastname: Rodriguez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000068818:Cetuximab / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D010039:Otorhinolaryngologic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D000068818:Cetuximab
keywords: Cetuximab; head and neck; paclitaxel; squamous cell carcinoma